Figure 1
(A) Progression-free survival (PFS) and (B) overall survival (OS) of all eligible patients (n=28). The median PFS was 11.5 months. The median OS has not yet been reached. The 1-year survival rate was 79%.
Figure 1 | British Journal of Cancer
